Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
Curr Drug Metab. 2020;21(7):534-540. doi: 10.2174/1389200221666200711160440.
BACKGROUND: Chloroquine has been used to treat malaria for more than 70 years. Its safety profile and cost-effectiveness are well-documented. Scientists have found that chloroquine has in vitro activity against novel coronavirus (SARS-CoV-2). Currently, chloroquine has been adopted in the Protocol for Managing Coronavirus Disease 2019 (COVID-19) (Version 7) issued by the China National Health Commission for clinically managing COVID-19. OBJECTIVE: This review will focus on the antiviral mechanism, effectiveness and safety, dosage and DDIs of chloroquine, for the purpose of providing evidence-based support for rational use of chloroquine in the treatment of COVID-19. METHODS: Use the search terms "chloroquine" linked with "effectiveness", "safety", "mechanism", "drug-drug interaction (DDIs)" or other terms respectively to search relevant literature through PubMed. RESULTS: After searching, we found literature about antivirus mechanism, dosage, DDIs of chloroquine. However, studies on the effectiveness and safety of chloroquine treatment for COVID-19 for the general and geriatric patients are not enough. CONCLUSION: According to literature reports, chloroquine has been proven to have anti-SARS-CoV-2 effect in vitro and the potential mechanism of chloroquine in vivo. Pharmacokinetic characteristics and DDIs study are helpful in guiding rational drug use in general and geriatric patients. Although there have been reports of successful clinical application of chloroquine in the treatment COVID-19, more clinical test data are still needed to prove its effectiveness and safety.
背景:氯喹用于治疗疟疾已有 70 多年的历史,其安全性和成本效益已得到充分证实。科学家发现氯喹对新型冠状病毒(SARS-CoV-2)具有体外活性。目前,氯喹已被中国国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第七版)》用于临床治疗新型冠状病毒肺炎。
目的:本综述将重点关注氯喹的抗病毒机制、疗效和安全性、剂量和药物相互作用(DDI),为合理使用氯喹治疗新型冠状病毒肺炎提供循证支持。
方法:通过 PubMed 分别使用搜索词“氯喹”与“疗效”“安全性”“机制”“药物相互作用(DDI)”等进行相关文献检索。
结果:检索后发现了关于氯喹抗病毒机制、剂量、DDI 的文献,但氯喹治疗新型冠状病毒肺炎的疗效和安全性在普通人群和老年人群中研究不足。
结论:根据文献报道,氯喹已被证明具有体外抗 SARS-CoV-2 作用,以及体内氯喹的潜在作用机制。药代动力学特征和 DDI 研究有助于指导普通人群和老年人群的合理用药。虽然已有氯喹治疗新型冠状病毒肺炎成功的临床应用报道,但仍需要更多的临床研究数据来证实其疗效和安全性。
Antiviral Res. 2020-3-5
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2020-4-22
Crit Care. 2020-5-8
Expert Rev Anti Infect Ther. 2020-7-13
Ned Tijdschr Geneeskd. 2020-6-2
Int J Antimicrob Agents. 2020-3-12
Ned Tijdschr Geneeskd. 2020-3-11
Rev Med Suisse. 2020-3-11
Med Mal Infect. 2020-5